Vantage Investment Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vantage Investment Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-128	Closed	-$2K	–	835
2016 Q3	$2K	Sell	128 -2	-2%	-$19	﹤0.01%	695
2016 Q2	$1K	Hold	130	–	–	﹤0.01%	778
2016 Q1	$1K	Hold	130	–	–	﹤0.01%	767
2015 Q4	$2K	Hold	130	–	–	﹤0.01%	701
2015 Q3	$8K	Hold	130	–	–	﹤0.01%	544
2015 Q2	$10K	Sell	130 -129	-50%	-$10.8K	0.01%	480
2015 Q1	$18K	Buy	259 +129	+99%	+$11.1K	0.01%	505
2014 Q4	$12K	Hold	130	–	–	0.01%	468
2014 Q3	$14K	Hold	130	–	–	0.01%	429
2014 Q2	$19K	Hold	130	–	–	0.01%	388
2014 Q1	$20K	Buy	+130	New	+$25.6K	0.01%	345

Other funds holding MDGL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Vantage Investment Advisors's MDGL Position: Q4 2016 in Review

Vantage Investment Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2016, closing a stake of 128 shares — an estimated $2K sold.

Vantage Investment Advisors first reported a position in MDGL in Q1 2014 and held it in 11 quarters. The position peaked at $20K in Q1 2014. 31 funds tracked by Wall St. Rank hold MDGL as of Q4 2016.

Vantage Investment Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Vantage Investment Advisors sold 128 Madrigal Pharmaceuticals shares in Q4 2016, an estimated $2K.
Vantage Investment Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Vantage Investment Advisors's Madrigal Pharmaceuticals position peaked at $20K in Q1 2014.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2016.

Based on Vantage Investment Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.